e-learning
resources
Virtual 2020
Pre-Congress Content
Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry
J. Gao (Stockholm, Sweden), D. Kalafatis (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), C. Li (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), M. Sköld (Stockholm, Sweden)
Source:
Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session:
Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session type:
E-poster session
Number:
1843
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Gao (Stockholm, Sweden), D. Kalafatis (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), C. Li (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), M. Sköld (Stockholm, Sweden). Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry. 1843
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Source: ERJ Open Res, 5 (3) 00170-2018; 10.1183/23120541.00170-2018
Year: 2019
Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
Survival predictors in a cohort of patients with idiopathic pulmonary fibrosis biopsy-proven
Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV
Year: 2012
Assessment of survival in patients with idiopathic pulmonary fibrosis (IPF) using quantitative HRCT indexes
Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Year: 2018
Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries.
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Genetic predictors of idiopathic pulmonary fibrosis (IPF) prognosis
Source: Eur Respir J 2006; 28: Suppl. 50, 830s
Year: 2006
Clinical course of idiopathic pulmonary fibrosis (IPF): Prediction and outcome
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Analysis of pulmonary function in patients with idiopathic pulmonary fibrosis (IPF): how stable is stable IPF?
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009
Longitudinal observation of idiopathic pulmonary fibrosis (IPF) patients cohort from one center in Poland.
Source: International Congress 2019 – Interstitial lung disease registries
Year: 2019
A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Source: International Congress 2016 – IPF treatment I
Year: 2016
Central European idiopathic pulmonary fibrosis (IPF) patients survey
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment I
Year: 2016
Disease characteristics and outcomes in a Swedish cohort of patients with pulmonary fibrosis (PF)
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018
First insights from the BTS idiopathic pulmonary fibrosis (IPF) registry
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept